Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104020 | 0.80 | POLB (0.40) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL3590647 | 0.80 | POLB (0.40) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL10303857 | 0.78 | POLB (0.43) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL17121284 | 0.74 | POLB (0.41) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL19215358 | 0.72 | ALDH1A1 (0.42) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL14548729 | 0.71 | POLB (0.47) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL7687818 | 0.70 | POLB (0.37) | POLBALDH1A1DDAH1KMT2ATAAR1 | |
| SCHEMBL1103811 | 0.68 | ALDH1A1 (0.35) | POLBABCC4MAPTALDH1A1DDAH1 | |
| SCHEMBL12023471 | 0.68 | NAAA (0.35) | POLBABCC4MAPTDDAH1TAAR1 | |
| SCHEMBL3588661 | 0.68 | EPHX2 (0.32) | ABCC4MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040562-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R&D IRELAND (IE) | 2014-09-11 | — | — | US | disclosed |
| US-8741926-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-03 | — | — | US | disclosed |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | POLB 2176/4885ABCC4 1022/4885MAPT 4865/4885 |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | POLB 2176/4885ABCC4 1022/4885MAPT 4865/4885 |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | POLB 2176/4885ABCC4 1022/4885MAPT 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.